Dark chocolate or tomato extract for prehypertension: a randomised controlled trial

Discipline of General Practice, The University of Adelaide, Adelaide, SA 5005, Australia.
BMC Complementary and Alternative Medicine (Impact Factor: 1.88). 02/2009; 9:22. DOI: 10.1186/1472-6882-9-22
Source: PubMed

ABSTRACT Flavanol-rich chocolate and lycopene-rich tomato extract have attracted interest as potential alternative treatment options for hypertension, a known risk factor for cardiovascular morbidity and mortality. Treatment of prehypertension (SBP 120-139/DBP 80-89 mmHg) may forestall progression to hypertension. However, there has been only limited research into non-pharmacological treatment options for prehypertension. We investigated the effect of dark chocolate or tomato extract on blood pressure, and their acceptability as an ongoing treatment option in a prehypertensive population.
Our trial consisted of two phases: a randomised controlled three-group-parallel trial over 12 weeks (phase 1) followed by a crossover of the two active treatment arms over an additional 12-week period (phase 2). Group 1 received a 50 g daily dose of dark chocolate with 70% cocoa containing 750 mg polyphenols, group 2 were allocated one tomato extract capsule containing 15 mg lycopene per day, and group 3 received one placebo capsule daily over 8 weeks followed by a 4-week washout period. In phase 2 the active treatment groups were crossed over to receive the alternative treatment. Median blood pressure, weight, and abdominal circumference were measured 4-weekly, and other characteristics including physical activity, general health, energy, mood, and acceptability of treatment were assessed by questionnaire at 0, 8 and 20 weeks. We analysed changes over time using a linear mixed model, and one time point differences using Kruskal-Wallis, Fisher's-Exact, or t-tests.
Thirty-six prehypertensive healthy adult volunteers completed the 6-month trial. Blood pressure changes over time within groups and between groups were not significant and independent of treatment. Weight and other characteristics did not change significantly during the trial. However, a marked difference in acceptability between the two treatment forms (chocolate or capsule) was revealed (p < 0.0001). Half of the participants allocated to the chocolate treatment found it hard to eat 50 g of dark chocolate every day and 20% considered it an unacceptable long-term treatment option, whereas all participants found it easy and acceptable to take a capsule each day for blood pressure.
Our study did not find a blood pressure lowering effect of dark chocolate or tomato extract in a prehypertensive population. Practicability of chocolate as a long-term treatment option may be limited. Identifier: ACTRN12609000047291.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular disease (CVD) is a major contributor to morbidity and mortality in the United States and worldwide. A link between diet and CVD is well established, with dietary modification a foundational component of CVD prevention and management. With the discovery of bioactive components beyond the essential nutrients of foods, a new era of nutritional, medical, botanical, physiologic, and analytical sciences has unfolded. The ability to identify, isolate, purify, and deliver single components has expanded the dietary supplement business and health opportunity for consumers. Lycopene is an example of a food component that has attracted attention from scientists as well as food, agriculture, and dietary supplement industries. A major question, however, is whether delivering lycopene through a supplement source is as effective as or more effective than consuming lycopene through whole food sources, specifically the tomato, which is the richest source of lycopene in the Western diet. In this review, we examined clinical trials comparing the efficacy of lycopene supplements with tomato products on intermediate CVD risk factors including oxidative stress, inflammation, endothelial function, blood pressure, and lipid metabolism. Overall, the present review highlights the need for more targeted research; however, at present, the available clinical research supports consuming tomato-based foods as a first-line approach to cardiovascular health. With the exception of blood pressure management where lycopene supplementation was favored, tomato intake provided more favorable results on cardiovascular risk endpoints than did lycopene supplementation. Indeed, future research that is well designed, clinically focused, mechanistically revealing, and relevant to human intake will undoubtedly add to the growing body of knowledge unveiling the promise of tomatoes and/or lycopene supplementation as an integral component of a heart-healthy diet.
    Advances in Nutrition 09/2014; 5(5):457-85. DOI:10.3945/an.114.005231 · 3.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: CVD is the leading cause of death in industrialized countries and entails increase cost of health care. Primary pre- vention, early reduction of risk factors and lifestyle modification implies the most significant decrease in cardiovascular disease associated mortality and morbidity. At the level of population strategy, the consumption of vegetables and fruits, including tomatoes might have an influence on the reduction in the risk of cardiovascular diseases mediated by reduction of body mass and lipid profile improvement. Tomatoes are an important source of bioactive compounds which can be divided into three groups: carotenoids, vita- mins, phenols. Standardized tomato extract (STE) comprises of those chemicals in high concentrations which are obtained due to modern technologies. There have been many studies that have shown anti-inflammatory, antioxidant, antitumor and endothelium protective properties of carotenoids, the most important fact is that a diet rich in tomatoes may have a beneficial effect on the cardiovascular system by inhibiting platelet aggregation. Inhibiting platelet caused by ADP-, collagen-, and arachidonic acid -related aggregation is mediated by decrease of releasing platelet factor 4 (PF4) or via increase of intracellular cAMP concentration. Active chemicals contained in STE may delay the occurrence of atherosclerotic lesions signi- ficantly. Furthermore, recent studies have reported that a standardized extract of tomato has a blood pressure lowering properties due to the inhibitory activity of angiotensin I converting enzyme (ACE). Tomato extract due to the lack of interaction and side effects, and due to the effectiveness confirmed in the research might be an alternative antiplatelet prophylaxis option instead of ASA (acetylsalicylic acid) in primary prevention of cardiovascular disease, especially in those cases where ASA usage is related with risk of side effects. In hypertensive patients STE may be considered in difficult-to-control hypertension, especially in high-risk group of patient with numerous risk factor, organ damage or comorbidites such as: diabetes mellitus, overweight or obesity. It should be emphasized that, the can be used as an additional therapy to aspirin and other antiplatelet drugs.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Export Date: 18 October 2014
    01/2013; 2013. DOI:10.1155/2013/289392

Full-text (3 Sources)

Available from
May 31, 2014